drugset / Trial / NCT03272217
Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer
Phase 2
Terminated
16 enrolled
Arjun Balar, MD
Hoosier Cancer Research Network · collabRoche-Genentech · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase II study assessing the activity of bevacizumab combined with atezolizumab in metastatic urothelial carcinoma patients who are ineligible for cisplatin-based therapy.
Timeline
- Start
- 2017-09-13
- Primary completion
- 2021-05-27
- Completion
- 2022-03-17
Outcome
Outcome not reported
Stopped (Business): “Funder decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |